RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On June 14, 2017, RespireRx Pharmaceuticals Inc. (the Company)
announced that the Companys President, Chief Executive Officer
and Vice Chairman of the Board of Directors, James S. Manuso,
Ph.D., will be presenting at the 2017 Marcum MicroCap Conference.
Dr. Manuso is scheduled to present at 10:00 a.m. Eastern Time on
Friday, June 16, 2017. The Conference is organized by Marcum LLP,
an independent public accounting and advisory services firm and
is being held at the Grand Hyatt Hotel in New York, New York on
June 15 and 16, 2017.
The slide presentation that Dr. Manuso will be using at the
conference is attached as Exhibit 99.1 and is being furnished and
not filed to Item 7.01 of Form 8-K. The presentation will be
available by live webcast that can be accessed by clicking on the
investors tab on the Companys website (www.respirerx.com) and
following the links and instructions in the press release
announcing this presentation, or by going to:
http://www.wsw.com/webcast/marcum5/rspi.
The webcast replay will be archived for 90 days. The press
release announcing the Companys participation in the conference
is attached as Exhibit 99.2 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
A list of exhibits that are furnished and filed as part of this
report is set forth in the Exhibit Index, which is presented
elsewhere in this document, and is incorporated herein by
reference.
About RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI)
RespireRx Pharmaceuticals Inc., formerly Cortex Pharmaceuticals, Inc., is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is focused on the clinical development in the areas of respiratory disorders, including respiratory depression and sleep apnea. It is engaged in research and clinical development of a class of compounds referred to as ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. Its ampakines, including CX717, CX1739 and CX1942, were efficacious in treating drug induced respiratory depression caused by opioids or certain anesthetics without offsetting the analgesic effects of the opioids or the anesthetic effects of the anesthetics. Its dronabinol is indicated for the treatment of sleep-related breathing disorders, including sleep apnea.
